Fulvio Gil
Vascular Neurology · Glenview, ILNPI 1801185822
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,147 of the $1,573 with a category attached, or 73.0%. 4 manufacturers reported payments, led by Janssen Research & Development, LLC at 48.7% of the total. Reporting peaked in 2023 at $767 and has fallen 96.0% since, to $31 in 2025. That places this record below the midpoint for vascular neurology clinicians in IL, where the typical reported total is $1,573.
Across 12 payments — averaging $131.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$767
- NICO Corporation$671
- Microtransponder, Inc.$105
- Novartis$31
Across 22 payments — averaging $4696.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$103K
What the payments were for
- Travel & lodging$1,14773%
- Food & beverage$42527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 8 | $767 |
| NICO Corporation | 2 | $671 |
| Microtransponder, Inc. | 1 | $105 |
| Novartis | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,573 in reported general payments places this provider in the 50th percentile of 32 vascular neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $27,884 |
| XareltoRivaroxaban | 11 | $11,083 |
| Levetiracetam | 64 | $2,594 |
| Lacosamide | 12 | $1,671 |
| Pregabalin | 16 | $1,236 |
| Gabapentin | 48 | $1,092 |
| Atorvastatin Calcium | 104 | $891 |
| Escitalopram Oxalate | 29 | $767 |
| ClopidogrelClopidogrel Bisulfate | 38 | $599 |
| Rosuvastatin Calcium | 42 | $533 |
| Memantine Hcl | 24 | $515 |
| Donepezil Hcl | 35 | $317 |
| Pantoprazole Sodium | 11 | $176 |
| Topiramate | 13 | $158 |
| Venlafaxine Hcl | 13 | $141 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Glenview
- Tareq Kass-HoutChicago$336K
- Phillip GorelickChicago$269K
- Richard BernsteinChicago$114K
- Jason DayOak Lawn$86K
- Mircea IacobWinfield$50K
- Yvonne CurranChicago$26K
- Fan CaprioChicago$9K
- Lesli SkolarusChicago$8K
- Naim KhourySpringfield$8K
- Sarah ParkerPeoria$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.